80
Participants
Start Date
June 30, 2013
Primary Completion Date
July 31, 2016
Study Completion Date
June 30, 2017
40 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
Standard of care MMC mixed with water
Standard of care 40mg MMC mixed with water
80 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
Carmel Medical Center of Haifa, Department of Urology, Haifa
Rambam Health Care Campus, Haifa
Wolfson Medical Center of Holon, Department of Urology, Holon
Meir medical center, Kfar Saba
Galil Maaravi Medical Center of Nahariya, Department of Urology, Nahariya
Rabin Medical Center of Petah Tikva, Department of Urology, Petach Tikvah
Ziv Medical Center, Safed
Vita Salute University, San Raffaele Hospital of Milan, Department of Urology, Milan
S. Andrea Hospital of Rome, Department of Urology, Rome
Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno
Fundacio Puigvert, Barcelona
Hospital Universitario Infanta Sofìa of Madrid, Department of Urology, Madrid
Hôpital HUG of Geneva, Department of Urology, Geneva
UroGen Pharma Ltd.
INDUSTRY